Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Neuropharmacology. 2019 Jul 26;158:107727. doi: 10.1016/j.neuropharm.2019.107727

Figure 7. The effects of r-Slit2 on apoptosis via the Slit2/Robo1/srGAP1/RhoA signaling pathway at 48h post HIE.

Figure 7.

(A) Representative picture of western blot data showing bands of the expression levels of Slit2, Robo1, srGAP1, RhoA, Bcl2, Bax and cleaved caspase3/caspase3 either with r-Slit2 treatment alone, r-Slit2+scramble si-RNA, r-Slit2+Recombinant Robo1, r-Slit2+si-GAP1 (B-G) Western blot data quantification of bands showed that r-Slit2 significantly increased Robo1 and srGAP1 expression levels when compared to vehicle. Recombinant Robo1 significantly reduced Robo1 receptor expression levels. Furthermore, siRNA for srGAP1 showed to significantly reduce srGAP1 when compared to treatment group. Treatment with r-Slit2 showed to significantly reduce RhoA, Bax and ratio of C-Cas3/Cas3 while the two interventions reversed this effect. (Data represent +/− SD; *p<0.05 versus sham, # versus vehicle; & versus r-slit2, n=6/group using one-way or two-way ANOVA followed by Tukey multiple-comparison post hoc analysis).